Hepatorenal Syndrome Treatment Market Growth Trajectory – Insights On Key Drivers, Major Trends, And Top Opportunities
18 Jul, 2023
The global hepatorenal syndrome treatment market size is expected to grow from $13.06 billion in 2022 to $13.85 billion in 2023 at a compound annual growth rate (CAGR) of 6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hepatorenal syndrome treatment market size is expected to reach $17.31 billion in 2027 at a CAGR of 5.7%.
Global Hepatorenal Syndrome Treatment Market Key Driver
An increase in the number of patients suffering from liver disease or cirrhosis is projected to drive the growth of the hepatorenal syndrome therapy market in the future. Cirrhosis is a severe form of liver disease in which scar tissue replaces healthy liver tissue permanently. The goal of hepatorenal syndrome treatment is to keep the patient's kidney function while reducing the disorder's symptoms and side effects. These measures may help you improve your general health and qualify for liver transplant surgery.
Get a sample of the global hepatorenal syndrome treatment market reportGlobal Hepatorenal Syndrome Treatment Market Segments
The global hepatorenal syndrome treatment market is segmented:
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
4) By Geography: The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global hepatorenal syndrome treatment market.
Major Hepatorenal Syndrome Treatment Industry Players
Becton, Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC., ESP Pharma Inc., PharmaIN Corporation, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences limited, Mount Sinai, NYU Langone Health, Max Healthcare
Get the full global hepatorenal syndrome treatment market report
Hepatorenal Syndrome Treatment Market Overview
Hepatorenal syndrome (HRS) is a multiorgan disorder characterized by acute kidney injury in patients with severe liver disease. Patients with this syndrome display signs and symptoms of liver failure in addition to decreased urination when they become oliguric.
Hepatorenal Syndrome Treatment Global Market Report 2023 provides data on the global hepatorenal syndrome treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The hepatorenal syndrome treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.